Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "Active"

1248 News Found

Mosaic Clinical Technologies’ AI breakthrough earns FDA “Breakthrough Device” designation
Medical Device | March 10, 2026

Mosaic Clinical Technologies’ AI breakthrough earns FDA “Breakthrough Device” designation

Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings


Lilly expands affordable access to diabetes & obesity medicines under new medicare programme
Supply Chain | March 10, 2026

Lilly expands affordable access to diabetes & obesity medicines under new medicare programme

Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans


FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis
Drug Approval | March 10, 2026

FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis

The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials


NATCO announces launch of Pomalidomide capsules in US
News | March 05, 2026

NATCO announces launch of Pomalidomide capsules in US

It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma


Rapid medical weight loss fuels surge in facial aesthetics, Allergan data shows
News | March 05, 2026

Rapid medical weight loss fuels surge in facial aesthetics, Allergan data shows

Recent data reveal that patients undergoing MWL are entering aesthetic practices with unique needs tied to facial structure and skin quality


AbbVie’s Risankizumab shows strong results in hard-to-treat Crohn’s disease patients
Clinical Trials | March 03, 2026

AbbVie’s Risankizumab shows strong results in hard-to-treat Crohn’s disease patients

This study evaluated a difficult-to-treat Crohn's disease patient population


Dabur backs luxury skincare startup RAS Beauty with Rs 60 crore investment
News | March 03, 2026

Dabur backs luxury skincare startup RAS Beauty with Rs 60 crore investment

The company has shown remarkable growth, posting a three-year CAGR of around 75% with an ARR of roughly Rs 100 crore and impressive gross margins